Diagnosing coinfection in pneumonia can be challenging because of timing of the sample collection and false-negative results when the viruses replicate in the lower respiratory tract.
Treatment with tocilizumab did not lead to improvement in clinical status and did not lower mortality at 28 days compared with placebo in hospitalized patients with severe pneumonia related to COVID-19.
Investigators assessed the cumulative incidence of acute cardiovascular complications during hospitalization for community-acquired pneumonia in internal medicine units.
The objective of this quasi-experimental observational study was to measure the effect of states’ hospital worker influenza vaccination laws on pneumonia and influenza mortality.
Findings from a retrospective chart review showed a need to carefully monitor inflammatory biomarkers and anticoagulant dosage in patients with severe COVID-19.
The REMDACTA study evaluated the efficacy and safety of tocilizumab plus remdesivir in hospitalized patients with severe COVID-19 pneumonia receiving standard of care.
There appears to be a low risk of invasive fungal secondary infection, especially aspergillosis, in patients with SARS-CoV-2-related pneumonia and no underlying immunosuppression.
The authors described the cases of 3 patients with moderate to severe COVID-19 pneumonia who were treated with 2g of icosapent ethyl administered twice daily via a nasogastric tube.
Study authors assessed the efficacy and safety of cefiderocol vs best available therapy in adults with serious carbapenem-resistant Gram-negative infections.
